| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6135857 | Microbes and Infection | 2013 | 10 Pages |
Abstract
To distinguish active from inactive/chronic infection in Toxoplasma gondii-seropositive individuals, we have developed an enzyme-linked immunosorbent assay (ELISA) using specific peptides derived from Toxoplasma matrix antigen MAG1. We used this assay to measure matrix specific antibodies and pilot studies with infected mice established the validity of two peptides. The immune response against MAG1 occurs in about 12 days postinfection and displays a sex difference later on in mouse model, with males producing higher antibody titers than females. Serum samples from 22 patients with clinical toxoplasmosis and from 26 patients with serological evidence of past exposure to Toxoplasma (more than one year infection history) were analyzed. Both MAG1 peptides detected antibodies significant frequently and robustly from active stage than from the chronic stage of toxoplasmosis. The results indicate that both MAG1 peptides may be used as a tool to differentiate active from inactive infection. It also may be considered in the design of potential vaccines in humans.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Jianchun Xiao, Raphael P. Viscidi, Geetha Kannan, Mikhail V. Pletnikov, Ye Li, Emily G. Severance, Robert H. Yolken, Laurence Delhaes,
